<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002738</url>
  </required_header>
  <id_info>
    <org_study_id>95-093</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-95093</secondary_id>
    <secondary_id>NCI-V96-0840</secondary_id>
    <nct_id>NCT00002738</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as trimetrexate glucuronate and leucovorin, use&#xD;
      different ways to stop cancer cells from dividing so they stop growing or die. Combining more&#xD;
      than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating&#xD;
      children with recurrent acute lymphoblastic leukemia, recurrent osteosarcoma, or refractory&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of trimetrexate glucuronate with leucovorin calcium rescue in&#xD;
           children with recurrent acute lymphoblastic leukemia, recurrent osteogenic sarcoma, or&#xD;
           refractory non-Hodgkin's lymphoma resistant to methotrexate.&#xD;
&#xD;
        -  Evaluate the toxicity of this treatment regimen in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease (acute lymphocytic leukemia,&#xD;
      non-Hodgkin's lymphoma vs osteogenic sarcoma).&#xD;
&#xD;
      Patients receive trimetrexate glucuronate orally or IV every 12 hours on days 1-21 and oral&#xD;
      leucovorin calcium every 12 hours on days 1-24. Treatment repeats every 4 weeks. Patients&#xD;
      with stable or responsive disease may receive up to 4 courses of therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimetrexate glucuronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologic evidence of one of the following malignancies that has failed conventional&#xD;
             therapy:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma with bone marrow involvement&#xD;
&#xD;
               -  Osteogenic sarcoma&#xD;
&#xD;
          -  In vitro transport resistance to methotrexate demonstrated by bone marrow aspirate&#xD;
             assay&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 and under at diagnosis&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocytopenia allowed with bone marrow involvement&#xD;
&#xD;
          -  Thrombocytopenia allowed with bone marrow involvement&#xD;
&#xD;
          -  Anemia allowed with bone marrow involvement&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  (unless due to disease)&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST no greater than 100&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior bone marrow transplantation allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 week since prior intrathecal treatment&#xD;
&#xD;
          -  At least 2 weeks since prior systemic chemotherapy and recovered&#xD;
&#xD;
               -  At least 10 days for rapidly proliferating leukemia (i.e., WBC greater than&#xD;
                  50,000)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Trippett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Trimetrexate</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

